Disturbed Balance in the Expression of MMP9 and TIMP3 in Cerebral Amyloid Angiopathy-related Intracerebral Haemorrhage

Overview

Journal Acta Neuropathol Commun

Publisher Biomed Central

Specialty Neurology

Date 2020 Jul 8

PMID 32631441

Citations 16

Authors

Lieke Jakel

H Bea Kuiperij

Lara P Gerding

Emma E M Custers

Emma van den Berg

Wilmar M T Jolink

Floris H B M Schreuder

Benno Kusters

Catharina J M Klijn

Marcel M Verbeek

Affiliations

Soon will be listed here.

Abstract

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of the amyloid β (Aβ) protein in the cerebral vasculature and poses a major risk factor for the development of intracerebral haemorrhages (ICH). However, only a minority of patients with CAA develops ICH (CAA-ICH), and to date it is unclear which mechanisms determine why some patients with CAA are more susceptible to haemorrhage than others. We hypothesized that an imbalance between matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) contributes to vessel wall weakening. MMP9 plays a role in the degradation of various components of the extracellular matrix as well as of Aβ and increased MMP9 expression has been previously associated with CAA. TIMP3 is an inhibitor of MMP9 and increased TIMP3 expression in cerebral vessels has also been associated with CAA. In this study, we investigated the expression of MMP9 and TIMP3 in occipital brain tissue of CAA-ICH cases (n = 11) by immunohistochemistry and compared this to the expression in brain tissue of CAA cases without ICH (CAA-non-haemorrhagic, CAA-NH, n = 18). We showed that MMP9 expression is increased in CAA-ICH cases compared to CAA-NH cases. Furthermore, we showed that TIMP3 expression is increased in CAA cases compared to controls without CAA, and that TIMP3 expression is reduced in a subset of CAA-ICH cases compared to CAA-NH cases. In conclusion, in patients with CAA, a disbalance in cerebrovascular MMP9 and TIMP3 expression is associated with CAA-related ICH.

Citing Articles

The role of neuroinflammation in cerebral amyloid angiopathy.

van den Brink H, Voigt S, Kozberg M, van Etten E EBioMedicine. 2024; 110:105466.

PMID: 39608058 PMC: 11648568. DOI: 10.1016/j.ebiom.2024.105466.

Differences in the cerebral amyloid angiopathy proteome in Alzheimer's disease and mild cognitive impairment.

Leitner D, Kavanagh T, Kanshin E, Balcomb K, Pires G, Thierry M Acta Neuropathol. 2024; 148(1):9.

PMID: 39039355 PMC: 11263258. DOI: 10.1007/s00401-024-02767-1.

Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy.

Vervuurt M, Kuiperij H, de Kort A, Kersten I, Klijn C, Schreuder F Alzheimers Res Ther. 2024; 16(1):108.

PMID: 38745197 PMC: 11092079. DOI: 10.1186/s13195-024-01473-0.

Detrimental Effects of ApoE ε4 on Blood-Brain Barrier Integrity and Their Potential Implications on the Pathogenesis of Alzheimer's Disease.

Kirchner K, Garvert L, Kuhn L, Bonk S, Grabe H, Van der Auwera S Cells. 2023; 12(21).

PMID: 37947590 PMC: 10649078. DOI: 10.3390/cells12212512.

Intracerebral Hemorrhage Among Blood Donors and Their Transfusion Recipients.

Zhao J, Rostgaard K, Lauwers E, Dahlen T, Ostrowski S, Erikstrup C JAMA. 2023; 330(10):941-950.

PMID: 37698562 PMC: 10498336. DOI: 10.1001/jama.2023.14445.

References

van Veluw S, Scherlek A, Freeze W, Ter Telgte A, van der Kouwe A, Bacskai B . Different microvascular alterations underlie microbleeds and microinfarcts. Ann Neurol. 2019; 86(2):279-292. PMC: 8722100. DOI: 10.1002/ana.25512. View

Vonsattel J, Myers R, Hedley-Whyte E, Ropper A, BIRD E, Richardson Jr E . Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol. 1991; 30(5):637-49. DOI: 10.1002/ana.410300503. View

Freeze W, Jacobs H, Schreuder F, van Oostenbrugge R, Backes W, Verhey F . Blood-Brain Barrier Dysfunction in Small Vessel Disease Related Intracerebral Hemorrhage. Front Neurol. 2018; 9:926. PMC: 6240684. DOI: 10.3389/fneur.2018.00926. View

Yabluchanskiy A, Ma Y, Padmanabhan Iyer R, Hall M, Lindsey M . Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda). 2013; 28(6):391-403. PMC: 3858212. DOI: 10.1152/physiol.00029.2013. View

Wang T, Fu W, Song S, Han Y, Yao L, Lu Y . Matrix metalloproteinase-9 gene polymorphisms and their interaction with environment on subarachnoid hemorrhage risk. Exp Biol Med (Maywood). 2018; 243(9):749-753. PMC: 5956669. DOI: 10.1177/1535370218775042. View

Wermer M, Greenberg S . The growing clinical spectrum of cerebral amyloid angiopathy. Curr Opin Neurol. 2017; 31(1):28-35. DOI: 10.1097/WCO.0000000000000510. View

Samarasekera N, Smith C, Salman R . The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011; 83(3):275-81. DOI: 10.1136/jnnp-2011-300371. View

Hernandez-Guillamon M, Martinez-Saez E, Delgado P, Domingues-Montanari S, Boada C, Penalba A . MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke. Brain Pathol. 2011; 22(2):133-41. PMC: 8029059. DOI: 10.1111/j.1750-3639.2011.00512.x. View

Esiri M, Wilcock G . Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry. 1986; 49(11):1221-6. PMC: 1029068. DOI: 10.1136/jnnp.49.11.1221. View

10.

Butler G, Apte S, Willenbrock F, Murphy G . Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. J Biol Chem. 1999; 274(16):10846-51. DOI: 10.1074/jbc.274.16.10846. View

11.

Lee J, Yin K, Hsin I, Chen S, Fryer J, Holtzman D . Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol. 2003; 54(3):379-82. DOI: 10.1002/ana.10671. View

12.

Attems J, Jellinger K, Lintner F . Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol. 2005; 110(3):222-31. DOI: 10.1007/s00401-005-1064-y. View

13.

Magaki S, Tang Z, Tung S, Williams C, Lo D, Yong W . The effects of cerebral amyloid angiopathy on integrity of the blood-brain barrier. Neurobiol Aging. 2018; 70:70-77. PMC: 6146962. DOI: 10.1016/j.neurobiolaging.2018.06.004. View

14.

Freeze W, Bacskai B, Frosch M, Jacobs H, Backes W, Greenberg S . Blood-Brain Barrier Leakage and Microvascular Lesions in Cerebral Amyloid Angiopathy. Stroke. 2019; 50(2):328-335. PMC: 6415745. DOI: 10.1161/STROKEAHA.118.023788. View

15.

Nagase H, Visse R, Murphy G . Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002. View

16.

Mandybur T . The incidence of cerebral amyloid angiopathy in Alzheimer's disease. Neurology. 1975; 25(2):120-6. DOI: 10.1212/wnl.25.2.120. View

17.

Rempe R, Hartz A, Bauer B . Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. J Cereb Blood Flow Metab. 2016; 36(9):1481-507. PMC: 5012524. DOI: 10.1177/0271678X16655551. View

18.

Kovari E, Charidimou A, Herrmann F, Giannakopoulos P, Bouras C, Gold G . No neuropathological evidence for a direct topographical relation between microbleeds and cerebral amyloid angiopathy. Acta Neuropathol Commun. 2015; 3:49. PMC: 4535376. DOI: 10.1186/s40478-015-0228-9. View

19.

Montaner J, Molina C, Monasterio J, Abilleira S, Arenillas J, Ribo M . Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003; 107(4):598-603. DOI: 10.1161/01.cir.0000046451.38849.90. View

20.

Hartz A, Bauer B, Soldner E, Wolf A, Boy S, Backhaus R . Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke. 2011; 43(2):514-23. PMC: 5761312. DOI: 10.1161/STROKEAHA.111.627562. View